Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.